Suggested remit: To appraise the clinical and cost effectiveness of Berotralstat within its marketing authorisation for preventing acute attacks of hereditary angioedema.
Status In progress
Process STA 2018
ID number 1624

Provisional Schedule

Expected publication 25 August 2021

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen


Companies sponsors BioCryst Pharmaceuticals (berotralstat)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups HAE UK
Professional groups British Society for Allergy & Clinical Immunology
  Royal College of Pathologists
  Royal College of Physicians
  United Kingdom Primary Immunodeficiency Network


Comparator companies Shire Pharmaceuticals (lanadelumab, Cinryze) (confidentiality agreement signed, participating)
  CSL Behring UK (Berinert) (confidentiality agreement not signed, not participating)
  Pharming Group N.V (Ruconest) (confidentiality agreement not signed, not participating)
  Sanofi (danazol) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
16 June 2021 Committee meeting: 1
06 October 2020 Invitation to participate
06 October 2020 In progress. Invitation to Participate issued.
23 July 2020 - 20 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance